English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background and purpose   GLORIA , a registry conducted with 375 advanced Parkinson's disease patients treated with levodopa‐carbidopa intestinal gel ( LCIG ) for 24 months in routine clinical care, demonstrated significant reductions from baseline in ‘off’ time and ‘on’ time with dyskinesia and improvements in the Non‐Motor Symptom Scale ( NMSS ) total and individual domain scores, and in Parkinson's Disease Questionnaire 8 item ( PDQ ‐8) total score.    Methods  Associations between baseline  NMSS  burden ( NMSB ), the multi‐domain  NMSS  total score and the  PDQ ‐8 total score were investigated for 233 patients. Baseline  NMSB  was assigned to five numerical categories defined by the  NMSS  total cutoff scores (0–20, 21–40, 41–60, 61–80 and >80). Pearson and Spearman correlations were calculated at month 24.    Results  The response of  LCIG  was assessed using validated criteria after 24 months. The proportion of patients decreasing ≥ 30  NMSS  score points was 47% in the most affected  NMSB  category ( NMSS  total score > 80). A positive association was noted between baseline  NMSB  and  NMSS  total score (0.57,  P  < 0.0001), as well as between  NMSS  total score and  PDQ ‐8 total score (0.46,  P  < 0.0001). Associations between improvements of the  NMSS  domain sleep/fatigue and  PDQ ‐8 total score (0.32,  P  = 0.0001) as well as between the  NMSS  domain mood/cognition and  PDQ ‐8 total score (0.37,  P  < 0.0001) were also shown.    Conclusions  This analysis demonstrated positive associations between  NMSS  baseline burden and improvements of non‐motor symptoms. Improvements of non‐motor symptoms were associated with improved quality of life in advanced parkinsonian patients during a 2‐year treatment with  LCIG  and reflect the long‐term non‐motor efficacy of this treatment.

european journal of neurology

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel